HC Wainwright Research Analysts Decrease Earnings Estimates for Zymeworks Inc. (NYSE:ZYME)

Zymeworks Inc. (NYSE:ZYME) – Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for shares of Zymeworks in a report issued on Wednesday, September 25th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.47) per share for the quarter, down from their prior forecast of ($0.45). HC Wainwright currently has a “Neutral” rating and a $12.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS and FY2025 earnings at ($2.05) EPS.

Zymeworks (NYSE:ZYME) last issued its earnings results on Thursday, August 1st. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The business had revenue of $19.24 million during the quarter, compared to analyst estimates of $23.16 million. During the same period in the previous year, the company posted ($0.76) EPS.

Separately, Stifel Nicolaus boosted their target price on Zymeworks from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, August 2nd.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $12.42 on Friday. Zymeworks has a one year low of $6.01 and a one year high of $13.27. The firm has a market capitalization of $878.16 million, a price-to-earnings ratio of -6.94 and a beta of 1.19. The business has a 50-day simple moving average of $11.28 and a 200 day simple moving average of $9.93.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. bought a new stake in Zymeworks during the 2nd quarter worth approximately $1,683,000. Perceptive Advisors LLC increased its holdings in Zymeworks by 55.2% during the 2nd quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock worth $14,192,000 after purchasing an additional 592,904 shares in the last quarter. Susquehanna Fundamental Investments LLC increased its holdings in Zymeworks by 8.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 59,523 shares of the company’s stock worth $507,000 after purchasing an additional 4,444 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Zymeworks by 13.2% in the second quarter. The Manufacturers Life Insurance Company now owns 22,695 shares of the company’s stock valued at $193,000 after acquiring an additional 2,653 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in shares of Zymeworks in the second quarter valued at approximately $1,626,000. 92.89% of the stock is owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.